Laurion Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Laurion Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,383	Closed	-$137K	–	653
2023 Q1	$137K	Sell	17,383 -81,632	-82%	-$609K	﹤0.01%	394
2022 Q4	$669K	Sell	99,015 -248,110	-71%	-$1.33M	﹤0.01%	343
2022 Q3	$5.04M	Sell	347,125 -122,875	-26%	-$1.72M	0.03%	250
2022 Q2	$4.63M	Hold	470,000	–	–	0.07%	171
2022 Q1	$6.93M	Hold	470,000	–	–	0.08%	142
2021 Q4	$6.22M	Buy	470,000 +350,000	+292%	+$5.57M	0.06%	177
2021 Q3	$2.09M	Hold	120,000	–	–	0.01%	437
2021 Q2	$2.88M	Hold	120,000	–	–	0.02%	335
2021 Q1	$3.08M	Buy	+120,000	New	+$3.15M	0.02%	388
2019 Q2	–	Sell	-58,871	Closed	-$1.69M	–	1038
2019 Q1	$1.69M	Buy	58,871 +28,670	+95%	+$621K	0.02%	416
2018 Q4	$596K	Buy	+30,201	New	+$607K	0.01%	664

Other funds holding KALV

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Laurion Capital Management's KALV Position: Q2 2023 in Review

Laurion Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2023, closing a stake of 17,383 shares — an estimated $137K sold.

Laurion Capital Management first reported a position in KALV in Q4 2018 and held it in 11 quarters. The position peaked at $6.93M in Q1 2022. 94 funds tracked by Wall St. Rank hold KALV as of Q2 2023.

Laurion Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Laurion Capital Management sold 17,383 KalVista Pharmaceuticals shares in Q2 2023, an estimated $137K.
Laurion Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2018 and held it in 11 quarters.
Laurion Capital Management's KalVista Pharmaceuticals position peaked at $6.93M in Q1 2022.
94 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2023.

Based on Laurion Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.